OKYO
OKYO Pharma Ltd ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$83.44M
P/E Ratio
—
EPS
$-0.11
Beta
-0.12
52W High
$3.35
52W Low
$1.06
50-Day MA
$1.78
200-Day MA
$2.22
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-6.26M |
| EBITDA | $-6.25M |
| Operating Margin | 0.00% |
| Return on Equity | -2969.00% |
| Return on Assets | -104.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.09 |
| Price-to-Book | 14.11 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $52.48M |
| Float | $23.72M |
| % Insiders | 30.41% |
| % Institutions | 9.00% |
Analyst Ratings
Consensus ($8.00 target)
1
Strong Buy3
BuyData last updated: 4/9/2026